Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Service

Funding, debt advisory & ECM

Parties

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Talk to the deal team

Bas Stoetzer

Partner

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Niels Vermuë

Associate Director

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Related deals

UKAT Group has acquired Bayberry Limited

Private Equity | Healthcare

UKAT Group has acquired Bayberry Limited

UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.

Learn more

Medicija has acquired Saulės Šeimos Medicinos Centras

Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more